Dr. D. Kyle Hogarth (University of Chicago Medical Center) and Dr. Amit Mahajan (Inova Fairfax Hospital) provided the field data. It represents the findings from 165 total patient procedures investigating 190 total lesions.
Key findings include diagnostic yield with a range of 92%-96% observed by Hogarth and 96% by Mahajan. The average lesion size ranged from 14mm to 16mm with more than a third less than or equal to 10mm in size. Approximately 88% and 75% of lesions navigated to and biopsied by Hogarth and Mahajan, respectively, appeared in the outer third or pleura of the lung.
Overall, the doctors reported that the average procedure time came in under 46 minutes at both locations.
San Carlos, California-based Noah Medical designed Galaxy and its accessories to provide bronchoscopic visualization and access. These capabilities provide diagnostic and therapeutic procedures in patient airways. The system features advanced imaging technologies that provide real-time location updates for potentially cancerous lesions. Noah designed the technology to improve tool-in-lesion and diagnostic yield.
Galaxy uses proprietary integrated tomosynthesis, called TiLT Technology. It enables augmented fluoroscopy with a disposable single-use bronchoscope with always-on vision, and a small, compact footprint that allows for easy integration into most bronchoscopy suites.
Read more about Noah Medical in our list of 10 surgical robotics companies you need to know.
More about the findings with the Noah Medical Galaxy system
Hogarth was the first user of Galaxy in the U.S., specializing in treating lung cancer and minimally invasive diagnosis. He chose the Galaxy system for its benefits in biopsying smaller peripheral lesions and its integrated imaging technology. This allows him to receive real-time lesion updates with only a C-arm.
“Using the Galaxy System over the past year, I have witnessed firsthand its incredible ability to correct for CT-to-body divergence and confirm tool-in-lesion through its integrated tomosynthesis technology, also known as TiLT technology,” Hogarth said in a news release. “Unlike first-generation robots, we can do this without purchasing additional expensive imaging technologies. I also appreciate the added confidence provided by its augmented fluoroscopy.”
Mahajan chose Galaxy for its capabilities in providing visualization of and access to patient airways, Noah Medical said. He believes it can improve diagnostic and therapeutic procedures, leading to better patient outcomes and improved economic and operational efficiencies.
“The Galaxy System offers the highest level of technology for diagnosing cancer early,” said Mahajan. “It is also financially sustainable, helping to minimize direct costs with its single-use bronchoscope while increasing the rate of cancer diagnosis.”
